Identification and quantitation of fexofenadine hydrochloride in model oral drops
- Authors: Bakri A.A.1, Zhilyakova E.T.1, Balloul G.1, Yousif A.Y.1, Taran A.V.1
-
Affiliations:
- Belgorod National Research University
- Issue: Vol 26, No 7 (2023)
- Pages: 41-45
- Section: Pharmaceutical chemistry
- URL: https://journals.eco-vector.com/1560-9596/article/view/568661
- DOI: https://doi.org/10.29296/25877313-2023-07-06
- ID: 568661
Cite item
Abstract
Relevance. Fexofenadine hydrochloride is a representative of the III generation of histamine H1 receptor blockers, therefore, it is not characterized by the disadvantages of antihistamines, such as: suppression of the central nervous system, cardiotoxic effect, headache, impaired coordination of movements, photosensitivity. Analysis of fexofenadine hydrochloride was performed using UV spectroscopy.
The purpose of the study – development of a new analytical method for the qualitative and quantitative identification of fixofenadine in drops for internal use.
Material and methods. The study used: fexofenadine, sodium hydroxide, water for injection, UV spectrophotometer type SF-104.
Results and conclusions. A method for the qualitative and quantitative determination of fexofenadine hydrochloride in model drops for internal use by the SPS method has been proposed. This method meets the requirements of OFS 1.1.0012.15 Validation of analytical methods, in terms of indicators: linearity and analytical area, correctness, precision.
Full Text
About the authors
Abdulhadi Ashour Bakri
Belgorod National Research University
Author for correspondence.
Email: EZhilyakova@bsu.edu.ru
Post-graduate Student, Department of Pharmaceutical Technology, Faculty of Pharmacy
Russian Federation, BelgorodE. T. Zhilyakova
Belgorod National Research University
Email: EZhilyakova@bsu.edu.ru
Dr.Sc. (Pharm.), Professor, Department of Pharmaceutical Technology, Faculty of Pharmacy
Russian Federation, BelgorodGhadeer Balloul
Belgorod National Research University
Email: ghadeerballoul@gmail.com
Master, Department Pharmaceutical and Chemical Technology
Russian Federation, BelgorodAbdullah Yahya Yousif
Belgorod National Research University
Email: EZhilyakova@bsu.edu.ru
Post-graduate Student, Department of Pharmaceutical Technology, Faculty of Pharmacy
Russian Federation, BelgorodA. V. Taran
Belgorod National Research University
Email: EZhilyakova@bsu.edu.ru
Ph.D (Pharm.), Senior Lecturer, Department of Pharmaceutical Technology
Russian Federation, BelgorodReferences
- Fouad M., Ragab M. Effectiveness and safety of fexofenadine in chronic idiopathic urticaria − open-label noncomparative study in daily practice. The Egyptian Journal of Dermatology and Venerology. 2017; 2(37): 43–48.
- Horn M.M., Nguyen A.L., Bielory L. Allergic conjunctivitis and dry eye syndrome. Ann Allergy Asthma Immunol. – 2012. 108 (3): P. 163-166.
- Van Cauwenberge P., Juniper E.F. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000 Jun; 30(6): 891–899. doi: 10.1046/j.1365-2222.2000.00914.x.
- Howarth P.H., Stern M.A., Roi L., Reynolds R., Bousquet J. Double-blind, placebocontrolled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999 Nov; 104(5): 927–933. doi: 10.1016/s0091-6749(99)70070-9. PMID: 10550734.
- Gross G.N., Ganster K., Meeves S., Liao Y., Georges G.C. A double-blind, randomized comparison of fexofenadine 180 mg versus cetirizine 10 mg: effect on instantaneous symptom score at the 24th hour. Ann Allergy Asthma Immunol. 2003; 90: 125.
- Hampel F., Ratner P., Mansfield L., Meeves S., Liao Y., Georges G. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91: 354–361.
- Sareen S., Mathew G., Joseph L. Improvement in solubility of poor water-soluble drugs by solid dispersion. Int. J. Pharm. Investig. 2012; 2(1): 12–17.
- Schoenwald R.D. Ocular pharmacokinetics. Textbook of Ocular Pharmacology; Lippincott-Raven: Philadelphia, PA, USA. 1997: 119–138.
- CH Topic Q 2 (R1) Validation of Analytical Procedures. Text and Methodology: June 1995, CPMP/ICH/381/95 / European Medicines Agency. London. 2006. 15 p. [Electronic resource]. Mode of access: http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2009/09/WC5000 02662.pdf.
- Gosudarstvennoj farmakopei Rossijskoj Federacii, OFS.1.1.0012.15 Validaciya analiticheskih metodik [In Russia] (Государственной фармакопеи Российской Федера-ции, ОФС.1.1.0012.15 Валидация аналитических методик).
- Uing G. Instrumental'nye metody analiza. Moskva: Mir, 1989. 608 s. [In Russia] (Юинг Г. Инструментальные методы анализа. Москва: Мир, 1989. 608 с.)
- Yakusheva E.N., Chernyh I.V., Shchul'kin A.V., Gacanoga M.V. Razrabotka VEZHKH-metodiki kolichestvennogo analiza feksofenadina v plazme krovi. Farmakokinetika i farmakodinamika. 2017; 2: 35–38. [In Russia] (Якушева Е.Н., Черных И.В., Щулькин А.В., Гацанога М.В. Разра-ботка ВЭЖХ-методики количественного анализа фексо-фенадина в плазме крови. Фармакокинетика и фармакодинамика. 2017; 2: 35–38.)
- Krishnan S.K., Veerasamy R., Thiyagu R., Dharamsi A., Raja M. Spectrophotometric Determination of Fexofenadine hydrochloride. Indian Journal of Pharmaceutical Sciences. 2006; 68(6): 841–842.
- Rajan V. UV Spectrophotometric Estimation of Fexofenadine hydrochloride by First Order Derivative and Area under Curve Methods in Bulk and Pharmaceutical Dosage Form. Der Pharmacia Lettre. 2016; 8(10): 95–101.
- British Pharmacopoeia 2009; Volume I and II; 2494–2500. 15. XIV.